Topics covered in EBM include: Anatomy/Pathology; Biochemistry and Molecular Biology; Cell and Developmental Biology; Endocrinology and Nutrition; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Bioimaging; Biomedical Engineering; Bionanoscience; Genomics, Proteomics, and Bioinformatics; Stem Cell Biology; Systems Biology, and Translational Research.
This journal is a member of the Committee on Publication Ethics (COPE)
Experimental Biology and Medicine (EBM) is a peer-reviewed journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. Published monthly, EBM provides both research and review articles as well as meeting symposia and brief communications. Articles in EBM represent cutting edge research at the overlapping junctions of the biological, physical and engineering sciences that impact upon the health and welfare of the world's population.
Topics covered in Experimental Biology and Medicine include: Anatomy/Pathology; Biochemistry and Molecular Biology; Cell and Developmental Biology; Endocrinology and Nutrition; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Bioimaging; Biomedical Engineering; Bionanoscience; Genomics, Proteomics, and Bioinformatics; Stem Cell Biology; Systems Biology, and Translational Research.
|Ian S. Zagon, PhD||Pennsylvania State University, USA|
|William Allen Banks, MD||VA Puget Sound Health Care System, USA|
|Lynda Bonewald, PhD||University of Kansas, Missouri, USA|
|Beverley Greenwood-Van Meerveld, PhD||The University of Oklahoma, College of Medicine, USA|
|Alexander V. Ljubimov, PhD, DSc,||Cedars-Sinai Med Ctr, Los Angeles, USA|
|Patricia J. McLaughlin, DEd||Penn State University College of Medicine, USA|
|Artur Pasternak, MD, PhD||Jagiellonian University Medical College, Poland|
|Douglas F. Paulsen, PhD||Morehouse School of Medicine, USA|
|Theodore Slotkin, PhD||Duke University Medical Center, USA|
|R. Alberto Travagli, PhD||Penn State Hershey Medical Center, USA|
|Muriel W. Lambert, PhD||Rutgers New Jersey Medical School, USA|
|Brian Adams, PhD||The Brain Institute of America, USA|
|Robert M. Brosh Jr., PhD||National Institutes of Health, USA|
|Shyamal D. Desai, PhD||Louisiana State University Health Sciences Center, USA|
|Shigemi Matsuyama, DVM, PhD||Case Western Reserve University, USA|
|Aleksander F. Sikorski, PhD||University of Wroclaw, Poland|
|Howard J. Worman, MD||Columbia University, USA|
|Shuliang Jiao, PhD||Florida International University, USA|
|Sanjiv Sam Gambhir, MD, PhD||Stanford University, Stanford, CA, USA|
|Ignacy Gryczynski, PhD||University of North Texas Health Science Center, USA|
|Zygmunt (Karol) Gryczynski, PhD||University of North Texas Health Science Center, USA|
|Hong Liu, PhD||University of Oklahoma, USA|
|Kate Luby-Phelphs, PhD||University of Texas Southwestern Medical Center, USA|
|Qingming Luo, PhD||Huazhong University of Science & Technology, Wuhan, China|
|Andreea Trache, PhD||Texas A&M Health Science Center, USA|
|Xinmai Yang, PhD||The University of Kansas, USA|
|Xincheng Yao, PhD||University of Illinois at Chicago, USA|
|Weizhao Zhao, PhD||University of Miami, Florida, USA|
|Horst A. von Recum, PhD||Case Western Reserve University, USA|
|Eun Ji Chung, PhD||University of Southern California, USA|
|Stuart L. Cooper, PhD||The Ohio State University, USA|
|F. Kurtis Kasper, PhD||University of Texas HSC, USA|
|Kam W. Leong, PhD||Duke University, USA|
|Angela Pannier, PhD||University of Nebraska, USA|
|Adam Perriman, PhD||University of Bristol, UK|
|Juan Andres Melendez, PhD||SUNY – Polytechnic Institute, USA|
|Nathaniel C. Cady||SUNY Polytechnic Institute, USA|
|Hassan A. N. El-Fawal, PhD||American University in Cairo, Egypt|
|Mark Kester, Ph.D.||University of Virginia, USA|
|Jonathan Lovell, PhD||University of Buffalo, USA|
|Gabriel A. Silva,PhD||University of California, San Diego, USA|
|Ya-Ping Sun, PhD||Clemson University, USA|
|M. Silvina Tomassone, PhD||Rutgers University, USA|
|Jie Zheng, PhD||The University of Texas at Dallas, USA|
|Siyang Zheng Ph.D.||Pennsylvania State University, USA|
|Peter J. Stambrook, PhD||University of Cincinnati Medical Center, USA|
|David A. Dean, PhD||University of Rochester, USA|
|Stephen C. Ekker, PHD||Mayo Clinic College of Medicine, USA|
|Leszek Kotula, MD||SUNY Upstate Medical University, USA|
|William E. Miller, PhD||University of Cincinnati College of Medicine, USA|
|Harold Ivan Saavedra PhD||Ponce Health Sciences University, Puerto Rico|
|Yigang Wang, M.D., Ph.D., F.A.H.A.||University of Cincinnati College of Medicine, USA|
|Warren E. Zimmer, PhD||Texas A&M University, USA|
|Nancy Turner, PhD||Michigan State University, USA|
|Clint Allred, PhD||Texas A&M University, USA|
|Mykola D. Khalangot, MD, PhD, ScD||Komisarenko Institute Of Endocrinology And Metabolism, Ukraine|
|Ramesh Narayan, PhD, MBA||University of Tennessee HSC, USA|
|B.L. Gregoire Nyomba, MD, PhD||University of Manitoba, Canada|
|Eugene Sobngwi, MD, MPh, PhD||University of Yaounde 1, Cameroon, Africa, Cameroon|
|Weiqun (George) Wang, PhD||Kansas State University, USA|
|William Slikker, Jr., PhD||US Food and Drug Administration, USA|
|Gary Steven Friedman, MD||Pfizer, Inc., USA|
|Donald J. Johann Jr., MD||University of Arkansas for Medical Sciences, USA|
|Lawrence J. Lekso, PhD, FCP||University of Florida, USA|
|Donna L. Mendrick, PhD||US Food and Drug Administration, USA|
|John-Michael Sauer, PhD||Critical Path Institute, USA|
|Cheng Wang, PhD||US Food and Drug Administration, USA|
|Paul Brent Watkins, MD||University of North Carolina, USA|
|Sulev Koks, MD, PhD||The Perron Institute for Neurological and Translational Science, Australia|
|Robert W. Williams, PhD||University of Tennessee HSC, USA|
|Mark Geraci, MD||University of Colorado, USA|
|Stephen J. Glatt, PhD||SUNY Upstate Medical University, USA|
|James Lyons-Weiler, PhD||University of Pittsburgh, USA|
|Momar Ndao, DVM, PhD||Montreal General Hospital, Canada|
|Heinrich Roder, PhD||Fox Chase Cancer Center, USA|
|Giovanni Stracquadanio, PhD||University of Essex, UK|
|Linda Barber, PhD||King's College London, UK|
|Andrea Doria, MD||University of Padova, Italy|
|Farzin Farzaneh, PhD||King's College London, UK|
|Kam Man Hui, PhD||National Cancer Centre Singapore, Singapore|
|Yoshio Koyanagi, MD, PhD||Institute for Virus Research, Kyoto University, Japan|
|Jacques-Olivier Pers, PhD||CHRU Morvan, France|
|Maria C. Villacres, PhD||University of Southern California, USA|
|Francois Villinger, PhD||Emory University, USA|
|Steven L. Youngentob, PhD||The University of Tennessee Health Science Center, USA|
|Santosh D'Mello, PhD||Southern Methodist University, USA|
|Terrence Deak, PhD||Binghamton University, USA|
|Alvaro Estevez, PhD||Cornell Medical Research Institute, New York, USA|
|Max L. Fletcher, II, PhD||University of Tennessee Health Science Center, USA|
|James Hewett, PhD||Syracuse University, USA|
|Sandra J. Hewett, PhD||Syracuse University, USA|
|Frank A. Middleton, PhD||SUNY Upstate Medical University, USA|
|Sandra Mooney, PhD||University of North Carolina, USA|
|Gregg D. Stanwood, PhD||Florida State University, USA|
|Mingqing Xu, PhD||Shanghai Jiao Tong University, China|
|Aaron Ciechanover, MD/PhD||The Technion Institute, Israel|
|Russell Hulse, PhD||The University of Texas at Dallas, USA|
|Y. James Kang, DVM, PhD||Sichuan University West China Hospital, China|
|Matthias Barton, MD||University Hospital Zurich, Switzerland|
|Guzel Bikbova, MD/PhD||Chiba Univesrity, Japan|
|Pawel Brzuzan, PhD||University of Warmia and Mazury in Olsztyn, Poland|
|Laetitia Dou, PhD||Aix-Marseille Universite, France|
|Vincent Samuel Gnana Prakasaiw, PhD||Manonmaniam Sundaranar University, India|
|Youngmi Jung, PhD||Pusan National University, Korea|
|Li-Fu Li, MD/PhD||Chang Gung Memorial Hospital and Chang Gung University, Taiwan|
|Jonathan Henry Shannahan, PhD||Purdue University, USA|
|Martin Sterba, PhD||Charles University Faculty of Medicine in Hradec Kralove,Czech Republic|
|Chaowu Xiao, PhD||Health Canada, Canada|
|Wuxiang Xie, PhD||Imperial College London, UK|
|Qihe Xu, MD/PhD||Kings College London, UK|
|Robert T. Mallet, PhD||University of North Texas, USA|
|R. Todd Alexander, MD/PhD||University of Alberta, Canada|
|Frantisek Kolar, PhD||Academy of Sciences of the Czech Republic, Czech Republic|
|Rong Ma, MD/PhD||University of North Texas Health Science Center, USA|
|Jiri Pacha, PhD||Academy of Sciences of Czech Republic, Czech Republic|
|Shaw-Jeng Tsai, PhD||National Cheng-Kung University Medical College, Taiwan|
|Samuel Verges, PhD||Hopital SUD, France|
|Tobias Wang, PhD||Aarhus University, Denmark|
|Lei Xi, MD||Virginia Commonwealth University, USA|
|Shaohua Yang, MD, PhD||University of North Texas Health Science Center, USA|
|Chunyu Zeng, MD||The Third Military Medical University, Chongqing City, China|
|Jian Feng, PhD||State University of New York at Buffalo, USA|
|Vania Broccoli, PhD||San Raffaele Scientific Institute, Milano, Italy|
|Jose Cibelli, DVM||Michigan State University, USA|
|Guoping Fan, PhD||University of California, Los Angeles, USA|
|Meri T. Firpo, PhD||University of Minnesota, USA|
|Antonis Hatzopoulos, PhD||Vanderbilt University, USA|
|Yoon-Young Jang, MD, PhD||Johns Hopkins University School of Medicine, USA|
|Dan S. Kaufman, MD||University of California, San Diego, USA|
|Mark Mercola, PhD||Burnham Institute for Medical Research, La Jolla, California, USA|
|Steven Stice, PhD||University of Georgia, USA|
|Chun-Li Zhang, PhD||UT Southwestern Medical Center, USA|
|Thomas B. Thompson, PhD||University of Cincinnati College of Medicine, USA|
|Andrew P. Hinck, PhD||University of Pittsburgh, USA|
|James R. Horn, PhD||Northern Illinois University, USA|
|Douglas John Kojetin, PhD||Scripps Florida, USA|
|Rhett A. Kovall, PhD||University of Cincinnati College of Medicine, USA|
|Vincent C. Luca, PhD||Moffitt Cancer Center & Research Institute, USA|
|Rick Page, PhD||Miami University, USA|
|Ana Carolina M. Zeri, PhD||Brazilian Biosciences National Laboratory, Brazil|
|Jenny C. Mortimer||Lawrence Berkeley National Laboratory, USA|
|John P. Wikswo, PhD||Vanderbilt University, USA|
|Rashid Bashir, PhD||University of Illinois, Urbana-Champaign, USA|
|Richard A. Gray, PhD||Food and Drug Administration, USA|
|Salman K. Khetani, PhD||University of Illinois at Chicago, USA|
|Philip R. LeDuc, MD||Carnegie Melon University, USA|
|Andre Levchenko, PhD||Yale Systems Biology Institute, USA|
|Peter Loskill, PhD||Fraunhofer Institute, Germany|
|D. Lansing Taylor, PhD||Director, University of Pittsburgh Drug Discovery, Institute and Distinguished Professor and Allegheny, Foundation Professor, Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA|
|Betty S. Pace, MD||Georgia Regents University, USA|
These instructions comply with the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/ebm to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Only manuscripts of sufficient quality that meet the aims and scope of Experimental Biology and Medicine will be reviewed.
As part of the submission process you will be required to state that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Experimental Biology and Medicine offers an English review service for authors submitting manuscripts. For more information about this low cost option visit http://www.EBMEnglishServices.squarespace.com or email email@example.com
Please find a PDF of the full Editorial Board here.
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper
- Editorial policies
2.1 Peer review policy
2.4 Financial support and conflict of interest
2.5 Research ethics
- Publishing policies
3.1 Publication ethics
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
- Preparing your manuscript
4.2 Supplementary material
4.3 Reference style
4.4 English language editing services
- Submitting your manuscript
5.1 Page charges
5.2 Online submission
5.4 Information required for completing your submission
- On acceptance and publication
6.1 SAGE Production
6.2 Online First publication
6.3 Access to your published article
6.4 Promoting your article
- Further information
Experimental Biology and Medicine is particularly appropriate for publication of papers that are multidisciplinary in nature, are of potential interest to a wide audience, and represent experimental medicine in the broadest sense of the term. However, manuscripts reporting novel findings on any topic in the realm of experimental biology and medicine are most welcome. We particularly encourage submission of manuscripts that describe results of studies that require an interdisciplinary approach to biomedical issues.
Categories currently listed in EBM are: Anatomy/Pathology; Biochemistry and Molecular Biology; Bioimaging; Biomedical Engineering; Bionanoscience; Cell and Developmental Biology; Endocrinology and Nutrition; Environmental Health/Biomarkers/Precision Medicine; Genomics, Proteomics, and Bioinformatics; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Stem Cell Biology; Structural Biology; Systems Biology and Microphysiological Systems; and Translational Research.
For more information on these topics please click here to review the category descriptions.
Authors should indicate their preference of category, although the final decision of reviewing Associate Editor and section Editorial Board rests with the Editor-in-Chief.
Original Research Articles: Manuscripts are accepted for review with the understanding that the same work has not been submitted or published elsewhere and, if accepted by EBM, will not be submitted or published elsewhere. If evidence of dual submission is found, the manuscript will be rejected or, if published, retracted.
Unnecessary subdivision of a study into several manuscripts is not acceptable. If any material published previously is included, for clarity or other reasons, this should be indicated with appropriate citation in the manuscript.
Previously published work: One copy of any material that might be regarded as "duplicate publication" such as preliminary reports (including reviews, symposia and proceedings) or other publications (submitted, in press or published) containing data or other material included in the submitted manuscript, must be sent to the Editor when the manuscript is submitted. Clearly label such material so as to avoid any confusion with the submitted manuscript. Normally it is regarded as acceptable to include in a detailed journal article material that has been presented previously in summary form in reviews, symposia, or conferences, provided appropriate citation is included.
Contact the Editorial office at firstname.lastname@example.org if you require further information.
Please note that Experimental Biology and Medicine does not accept submissions of papers that have been posted on pre-print servers.
Brief Communications: Manuscripts describing focused studies that are concise and of high impact to a field will be published as Brief Communications. This format is intended for the presentation of scientifically sound and novel research in a clear and concise fashion. The body of the paper should not exceed nine (9) pages of double-spaced text with references. Tables and Figures must also be kept to a minimum (no more than four). Formatting should otherwise follow the requirements for Original Research Articles.
Minireviews: The journal publishes review articles under the section heading "Minireviews." Although there is no page limit, the reviews are generally short (~20 pages of double-spaced text with references). They should reflect the state-of-the-art of the area being reviewed and often include a brief history of the field. There is no need to include an exhaustive literature survey. Emphasis upon a particular hypothesis or point of view or upon the personal opinions or interpretation of the writer or upon the work of the writer's laboratory is appropriate, provided that this focus is clearly indicated in the paper. Most reviews are submitted in response to an invitation from the Editor-in-Chief, and are subjected to the usual review process prior to publication. Unsolicited reviews and reviews solicited by the Associate Editors need to be approved by the Editor-in-Chief before receiving peer review.
Comments: The Journal, at the Editor-in-Chief's discretion, will publish, under the section heading "Comments", letters or essays from readers discussing articles that have recently appeared in the Journal or other timely topics of interest to the Journal's readership. The author of a letter or essay which is published accepts full responsibility for the contents of the letter. Letters discussing a published article may for example include supporting information, clarifications, criticisms, corrections, alternate interpretations or perspectives. Such letters will be sent to the corresponding author of that article prior to publication. If the corresponding or other author wishes, her/his response will be published together with the original letter. At the discretion of the editor, essays or letters discussing controversial issues may be sent to persons representing alternative viewpoints who will be encouraged to provide responses. If the Editor decides to publish such responses, they will be sent to the original author for comments prior to publication. In some cases, the Editor-in-Chief may send a letter or essay for outside review prior to deciding whether to publish it. The Society reserves the right to edit these communications without materially changing their meaning.
The SAGE Author Gateway has some general advice on how to get published, plus links to further resources.
1.3.1 Make your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
Two reviewers will generally evaluate each manuscript on the basis of scientific rigor of the experimental design, adequacy of the data, validity of the conclusions, importance and originality of the studies, adequacy of the literature citations, clarity of the presentation, and interest to the Journal's readership. Manuscripts may be returned to the authors without detailed review if, in the opinion of the Editor-in- Chief, they fall outside the scope of interests of the Journal's readership or if they are not written in clear, concise and grammatical English.
Manuscripts will be given a quality (priority) ranking by each reviewer. Those manuscripts with low priority rankings will not be accepted even though they may have been classed as generally acceptable. If reviewers differ significantly in their opinions, decision will be based on the priority rankings and/or the opinion of an additional reviewer (arbiter). Manuscripts returned after revision based upon reviewers' comments will be sent back to the original reviewers together with the authors' responses.
When, as a result of reviewers' comments, it is necessary to revise a manuscript, it is recommended that, unless additional studies are required, the authors should resubmit the revised manuscript promptly; a delay of longer than four months may result in the revised manuscript receiving a lower priority. If you have any questions regarding submission, please contact the SEBM office: Tel: 201-962-3519 e-mail: email@example.com
The reviewers' comments will be held in confidence except as follows: (a) the reviewers' comments may be sent, in whole or in part, to the corresponding author;(b)after revision, each reviewer's comments will be sent, in whole or in part, to the other reviewers of the manuscript: and (c) in the event that there is a significant difference in opinion between or among the reviewers, the manuscript may be sent to an additional reviewer (arbiter) together with the comments, in whole or in part, of the other reviewers. In all cases, anonymity of the reviewers will be maintained.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
All grant, contract and industrial support of the work included in the manuscript must be acknowledged. Commercial relationships of any of the authors that might be viewed as representing a conflict of interest must be disclosed in a footnote to the applicable author's name. Such disclosure should be made on a separate page as it will not be sent to reviewers or influence editorial decisions but will be included in the published paper.
Experimental Biology and Medicine requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Experimental Biology and Medicine to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that “The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article”. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Ethical approval: All research submitted for publication must be approved by an ethics committee.
Use of human and animal subjects and recombinant DNA: Studies involving human subjects must conform to the ethical standards set by the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research; must have been reviewed and approved by the appropriate institutional Review Board (IRB); and must be presented in such a manner as to assure preservation of the anonymity of the subjects. It must be stated in the Materials and Methods section of the article that the study had been approved by the responsible IRB and that informed consent was obtained from research subjects or it must be explained why IRB review and /or informed consent were not required. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
It is the Journal's policy that all studies involving the use of animals be conducted in compliance with applicable laws and regulations as well as the principles expressed in the National Institutes of Health, USPHS, Guide for the Care and Use of Laboratory Animals, and that the studies be conducted on animals that were lawfully acquired. Use of animals must have been approved by the Institution's Animal Care and Use Committee (IACUC) and this must be stated in the Materials and Methods section of the article. If the study was conducted in a jurisdiction where such review is not required, this should be noted in the Materials and Methods section. Experiments involving recombinant DNA must have been reviewed and approved as required by applicable laws and regulations.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
The knowing duplication of published work without appropriate attribution will not be tolerated. This policy covers all material, whether in the form of text, tables, figures or other exhibits, which has been published or is being considered for publication in another journal, and applies to the published work of the submitting author(s) as well as the work of other investigators.
Experimental Biology and Medicine and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
Three levels of plagiarism are covered by this policy, with progressively more severe sanctions: Level one: Limited duplication of text from the authors' own published work, with somewhat more relaxed stringency for materials and methods: In these cases, the manuscript will be returned to the authors with instructions to rewrite/rephrase the duplicated text, before publication of the submission may proceed. If the materials and methods are heavily duplicated, the authors could be advised to reference their published work, thereby shortening that section. Level two: Substantial duplication of an author's own work, or significant duplication of the work of others, will result in rejection of the manuscript or retraction after publication. Level three: Duplication of an author's own work so extensive that it could be considered an attempt to publish the same work twice (dual or redundant publication), or lifting of large chunks of text or data from the work of others, will result in rejection of the manuscript or retraction after publication and, in addition, contacting the appropriate officials at the author's institution.
Submitted manuscripts which, following the initial review, have a likelihood of eventual publication in EBM, will be evaluated by advanced plagiarism detection software, which systematically compares the manuscript against an extensive database of published literature. If the software identifies possible plagiarism, further investigation will be conducted by the Associate Editor of the assigned section of EBM. Findings of potential plagiarism requiring one of the sanctions described above will be forwarded to the Editor-in-Chief for further review. Every effort will be made to conduct these reviews in a careful, fair and impartial manner, to avoid inappropriate imposition of sanctions. EBM urges submitting authors to avoid duplication either of their own work or that of others, and recommends authors evaluate their manuscripts with plagiarism-detecting software before submitting their work to EBM.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Authors of accepted manuscripts will be required to assign copyright to the Society for Experimental Biology and Medicine (SEBM). For more information please visit the SAGE Author Gateway.
Experimental Biology and Medicine offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
The preferred format for your manuscript is Word. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
Manuscripts should be as concise as possible, yet sufficiently detailed to permit critical appraisal, and should generally not exceed 40 typed pages (including tables, charts and references). They must be submitted using 11 pt or larger font size, double line-spaced, unjustified text throughout, with headings and subheadings in bold case. Press 'Enter' only at the end of a paragraph, list entry or heading.
Covering letter: The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication; the letter should explain how your paper is innovative, provocative, timely, and of interest to a broad audience. The letter should list any paper on related topics by any of the authors that have been published within the past year or that are in review or in press. The letter must state that the non-signing author(s) have read and approved the manuscript. Any person cited in the manuscript as a source of "personal communication" or "unpublished data" must provide signed approval of such citation.
Main Document File: For research articles the Main Document file should include, in the following order, a Title Page, Abstract/Keywords, Impact Statement, Introduction, Materials and Methods, Results, Discussion, Author Contributions statement, Declaration of Conflict of Interest statement, Funding statement, Acknowledgements (if applicable), References and Figure Legends..
Title page: The first page should contain the full title of the manuscript, a short title, the author(s) name(s) and affiliation(s), and the name, postal and email addresses of the corresponding author,
The title should be a declarative statement of key findings and should be limited to 15 words. Use of abbreviations in the title should generally be avoided.
Abstract: An abstract of no more than 300 words must accompany all articles and should not be structured. Subheadings are not allowed in the Abstract.
Impact Statement: An Impact Statement is required for all submissions. It should be no more than 150 words and will be included as a boxed statement on the first page of the article, separate from the Abstract. The Impact Statement is not a restating of the abstract. It should address the following:
- Why is the work submitted important to the field?
- How does the work submitted advance the field?
- What new information does this work impart to the field?
- How does this new information impact the field?
Your impact statement will be evaluated by the Editor-in-Chief, Global Editors, and appropriate Associate Editor. They must be convinced that the manuscript is an important advance in your field for your manuscript to receive full review.
Tables: Tables must be submitted as separate individual files, Tables must be prepared using the Table feature of the word processor. Tables should not duplicate information given in the text, should be numbered with Arabic numerals and cited consecutively in the text. Each table should be titled and double-spaced on a separate sheet. Refer to current issues of Experimental Biology and Medicine for the acceptable style of tables. The title of each table should clearly indicate the nature of the contents, and sufficient experimental detail should be included in footnotes to the entries in the table to permit the reader to interpret the results without reference to the text. Units must be clearly indicated for each of the entries in the table.
Artwork, figures and other graphics: Figures must be submitted as separate individual files, All figures should be cited consecutively by Arabic numerals in the text with figure legends typed on a separate sheet. Legends should contain sufficient experimental detail to permit the figures to be interpreted without reference to the text. Units should be clearly indicated in the figures themselves. All figures and illustrations are to be submitted individually in such form as to permit photographic reproduction without retouching or redrawing. Line drawings should be no larger than 8.5 x 11.5 inches overall (21 x 27.5 cm). The lettering should be large enough to allow a reduction of two thirds.
Line drawings should be produced electronically and clearly labeled using sans serif font such as Arial. Graphs may be supplied as Excel spreadsheets (one per sheet). Other line drawings should be supplied in a suitable vector graphic file format (e.g. .eps).
For general guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in color will appear in colour online regardless of whether or not these illustrations are reproduced in color in the printed version. For specifically requested color reproduction in print, you will receive information regarding the costs after receipt of your accepted article. SEBM members in good standing at the time of submission will receive a discount on the color printing fee.
Manufacturer names: Please note that when manufacturer names are used in the text, the location (city, state, country) of the manufacturer should also be included.
Abbreviations: Symbols and abbreviations should be those currently in use. Authors should not create new abbreviations and acronyms.
Units: All measurements should be expressed in SI units.
Other conventions: Authors of manuscripts describing original nucleotide or amino acid sequences must submit the sequence to Gen Bank and obtain an accession number from Gen Bank before publication of the manuscript. The accession number should be included in the manuscript as a footnote or in the appropriate figure legend.
Statement of Author Contributions: Authors must include a statement that specifies the actual contribution of each co-author to the completed work. The Statement of Author Contributions and Acknowledgments should be typed on a separate page and placed at the end of the text pages. Formatting of this statement is illustrated by the following example:
"All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; MPV, MNS, KAM, and YZ conducted the experiments, RJS supplied critical reagents [or animals] (specify), RAS and WEZ wrote the manuscript, and XYZ contributed [other] (specify)."
Acknowledgments: Individuals whose contribution does not reach the level required for their inclusion as an author should be acknowledged in the traditional way, with their full names(s) given. For example, "The authors thank Dr. John Doe for advice in statistical analysis".
The corresponding author must verify that all individuals who made contributions to this study are included either as authors or are acknowledged at the end of the paper.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Citations should be used to provide appropriate attribution and credit to previous investigators. Authors are responsible for verifying them against the original source material. Extensive citation should be avoided, if possible, while adhering to the applicable conventions of the scientific community. Authors are responsible for obtaining permission to reproduce from the appropriate sources cited in the text. References should be arranged numerically at the end of the manuscript and cited in the text with superscript numerals. The references should be numbered consecutively in order of their citation and include the names and initials of all authors. Publications for which no author is apparent may be attributed to the organization from which they originate. Simply omit the name of the author for anonymous journal articles - avoid using 'Anonymous'. Experimental Biology and Medicine uses a modified version of the Vancouver referencing system; examples are shown below:
Zhang X, Wang J, Fan Y, Yang L, Wang L, Ma J. Zinc supplementation attenuates high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells. Biol Trace Elem Res 2012;150:229–35
Weatherall D, Clegg J. The molecular pathology of the thalassaemias. The Thalassaemia Syndromes, 4th ed. Oxford: Wiley-Blackwell, 2001, pp. 133–91
"Personal communication", "unpublished" and "submitted" must be excluded from the reference list and cited in a footnote. If a manuscript being cited has been accepted for publication, include it in the reference list, giving journal, volume, year as available. In general, citation of numerous abstracts is discouraged, although acceptable if necessary to provide proper attribution or credit.
Trade name, popular name or abbreviation when first used must be preceded by the chemical, scientific or technical name; thereafter, any of these names or abbreviations may be used. Trade names should begin with a capital letter. Structural formulas of chemicals should be used only when absolutely necessary.
If English is not your native language, you may find it helpful to obtain assistance in writing your papers before submitting them to EBM. This may not only save time in the review process but also increase the effectiveness of your submission. Quality of written English is judged by the Editor-in-Chief, Global Editors, and appropriate Associate Editor. They must be convinced that the quality of written English is sufficient for your manuscript to receive full review. EBM offers low-cost English services for authors.
Authors are required to pay a part of the cost of publication in the form of a page charge of $70 per page. There will be no page charges for articles where the first or corresponding author is an SEBM member in good standing at the time of manuscript submission. Authors lacking funding from grant or other sources may apply at the time of submission for a waiver of page charges. Apply for a waiver of page charges on institutional letterhead at the time of submission. The letter can be sent electronically to firstname.lastname@example.org Applications must be endorsed by a senior institutional official verifying that no funds are available for paying page charges. A waiver of page charges will not be granted once an initial decision has been rendered on the manuscript. Once a waiver has been approved and a paper published authors may not request a waiver for any future manuscripts.
Experimental Biology and Medicine is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/ebm to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the Journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Please note the following form must be completed on submission (these are available on the Journal’s submission site):
Tables and figures must be submitted as separate individual files, in which case the files should be uploaded in the following order: (1) main document (2) tables; (3) figures; and (4) supplementary files. The submission system will generate a PDF for the purposes of sending to reviewers; please review this file carefully and ensure your submission documents have been properly converted.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
You will be asked to provide valid email addresses, contact details, and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details, including the author order, must match what appears on the Title page of your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files.
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Corrections should be kept to a minimum. Authors will be charged for excessive changes. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.
SAGE provides authors with online access to their final article. A link is provided allowing the author to download the article directly from the SAGE website and forward the link onto their co-authors.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Experimental Biology and Medicine Editorial office at the following address: email@example.com